18

Click here to load reader

A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Embed Size (px)

DESCRIPTION

I. Definition n “ Meta-analysis is a relatively new method for reviewing and combining results from multiple clinical trials. Whereas other review methods usually involve narrative discussions of individual trials, a meta- analysis … systematically combines and evaluates the results of clinical trials that have been completed.” - Spilker, Guide to Clinical Trials, 1991, Chapter 104

Citation preview

Page 1: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

A Meta-Analysis Primer

Rick Chappell - 641, 12/15/2010

Page 2: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Outline

I. DefinitionII. Example 1 - Cervical Carcinoma at UWIII. How to Numerically Summarize EvidenceIV. Examples of PresentationV. Reasons for Meta-AnalysisVI. Problems with Meta-Analysis

Page 3: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

I. Definition

“Meta-analysis is a relatively new method for reviewing and combining results from multiple clinical trials. Whereas other review methods usually involve narrative discussions of individual trials, a meta-analysis … systematically combines and evaluates the results of clinical trials that have been completed.” - Spilker, Guide to Clinical Trials, 1991, Chapter 104

Page 4: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

A “systematic review” is:– Numeric– Complete

Often a separate publication Can be used in the Discussion of a trial

publication to compare its results with others’ and to summarize evidence

Page 5: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

II. Example 1 - Cervical Ca at UW

Does treatment prolongation change outcome?

If so, among which subgroups of patients?

(Example presented on Wed. 12/8)

Page 6: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Moral: the scientific method is not a democratic process.

Meta-analysis does not consist of “voting” for the most popular result.

P-values do not provide a proper summary of evidence - estimates do.

Page 7: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

III. How to Numerically Summarize Evidence

A. Continuous Outcomes - Difference in Means (usually) or medians.– Means are easy to combine: averaging

means gives you a new mean (unlike with medians)

– E.g., mean income is the average of mean male and mean female incomes (average may need to be weighted if # of males isn’t equal to # of females).

Page 8: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

B. Time to Event (“Survival”) Outcomes - Hazard Ratio (HR)

HR = (Probability of event in a short time period for a ‘treated’ patient) /

(Probability of event in a short timeperiod for an ‘untreated’ patient).

– Sometimes also called relative risk.– HRs may are often constant over a wide

range of risk levels.

Page 9: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

C. Binary Outcomes - Odds Ratio (OR)

Odds = (Probability of event) / (Probability of no event)

OR of event due to ‘treatment’ = (Odds of event given ‘treatment’) / (Odds when not given ‘treatment’)

Page 10: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Why are odds ratios commonly used?

They are useful in case-control studies (e.g., the odds of being an asbestos miner if you have mesothelioma are the same as the odds of having mesothelioma given you are an asbestos minor). This isn’t the reason here.

Statistical Reasons - ORs are easy to combine.

Like hazard ratios, ORs are often constant over a wide range of risk levels.

Page 11: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

IV. Examples of Presentation

Table of “O - E” (observed - expected in the ‘treatment’ group = excess incidence in that cohort). These can be added up.

Plot of trial # vs. odds ratio Both combined: “Forest plot”

Page 12: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Presentation ofMeta-analysis: Example

Clahsen, et al. JCO 115. pp. 2526-2535 (1997). Perioperative polychemotherapy (PeCT) in breast cancer.

Forest plot of hazard ratio (PeCT vs. no PeCT) of disease-free survival.

Page 13: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010
Page 14: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Example 3 - Berry, et al. (JCO, to appear)

Page 15: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

V. Reasons for Meta-Analysis(Armitage & Colton, Enc. of Biostatistics Vol. 4, 1999)

Narrative Reviews can be distorted and misleading.

Explosion of research evidence cannot be easily assimilated without a formal review.

Since individual CTs’ sample sizes may be too small to reliably detect clinically important effects, synthesis is necessary. Meta-analysis provides statistical power.

Page 16: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

VI. Problems with Meta-Analysis

Intertrial heterogeneity (see Table 104.1 of Spilker).

“Garbage in garbage out.” Publication bias - any relation between

the direction of study’s results and their dissemination.

Page 17: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

Publication Bias E.g., ORG-2766 protected nerves from

cytotoxic injury in 55 women with ovarian cancer - NEJM lead article (van der Hoop, et al., 1990); a subsequent negative study of 133 women - ASCO Proceedings abstract (Neijt, et al., 1994).

Vickers, et al. (1998) show that the problem is widespread: in some countries, 100% of publications show treatment effects.

Page 18: A Meta-Analysis Primer Rick Chappell - 641, 12/15/2010

An attempted Cure - The Cochrane Collaboration An international organization which

maintains complete registries and prepares reviews of research on clinical interventions.

Home page: www.cochrane.org or www.cochrane.de

Cochrane library: www.cochrane.co.uk